This article is more than 5 years old. Information may no longer be current.
Alcon posts double-digit sales gains in third quarter
Click Here to Manage Email Alerts
HUNENBERG, Switzerland — Alcon reported global sales of $1.07 billion for the third quarter of 2005, an increase of 11.8% from the third quarter of 2004, the company said in a press release. Net earnings for the quarter increased 52.2% to $295.8 million compared with net earnings of $194.3 million in the third quarter of 2004.
Pharmaceutical sales were $260.9 million in the United States and $176.9 million in the rest of the world; surgical sales were $225.3 million in the United States and $259 million in the rest of the world during the quarter.
Infection/inflammation medications earned $157.6 million, with glaucoma products close behind at $153.3 million in sales for the quarter. Cataract and vitreoretinal surgical products posted sales of $307.6 million, with IOLs at $165 million and refractive at $11.7 million.
Sales of glaucoma medication Travatan (travoprost) increased by 34.2%, and the company said its share of the prostaglandin market increased 3 share points in the United States. Sales of infection/inflammation products were led by Vigamox (moxifloxacin) and the launch of Nevanac (nepafenac). According to Alcon, Vigamox has a 44.9% market share of the fluoroquinolone category. Patanol (olopatadine) led allergy products, increasing its sales 3.4% during the quarter.
Sales growth in the IOL category rose 18.2% to $165 million, with the AcrySof Restor accommodating IOL posting sales of $17.5 million.